18F-Labeled PET Tracers Specific for Adenosine A2A Receptor: Design, Synthesis, and Biological Evaluation
Authors:
- 8 March 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 15 (6) , 1286-1297
Abstract
By modifying the structures of targeted A(2A)R antagonists and tracers, novel compounds 3, 7a, 9, 12c, and BIBD-399 were designed and synthesized. In vitro inhibition experiments demonstrated that 3, 12c, and BIBD-399 have high affinity for A(2A)R. [F-18]3 and [F-18]BIBD-399 were successfully synthesized. In terms of biological distribution, the brain uptake of [F-18]MNI-444 exhibits greater than that of [F-18]3 and [F-18]BIBD-399. PET imaging shows that [F-18]3 is off-target in the brain, while [F-18]BIBD-399 and [F-18]MNI-444 can be specifically imaged in regions with high A(2A)R expression. Differently, [F-18]BIBD-399 could quickly reach equilibrium in the targeted region within 10 min after administration, while [F-18]MNI-444 shows a slowly increasing trend within 2 h of administration. [F-18]BIBD-399 is mainly metabolized by the liver and kidney, and there is no obvious defluorination in vivo. Additional in vitro autoradiography showed that the striatal signals of [F-18]BIBD-399 and [F-18]MNI-444 were inhibited by the A(2A)R antagonist SCH442416 but not by the A(1)R antagonist DPCPX, demonstrating the high A(2A)R binding specificity of [F-18]BIBD-399. Molecular docking further confirms the high affinity of MNI-444 and BIBD-399 for A(2A)R. Further tMCAo imaging showed that [F-18]BIBD-399 can sensitively distinguish between infarcted and noninfarcted sides, a capability not observed with [F-18]MNI-444. Given its pharmacokinetic properties and the ability to identify lesion regions, [F-18]BIBD-399 has potential advantages in monitoring A(2A)R changes, meriting further clinical investigation.Keywords
Funding Information
- Natural Science Foundation of Beijing Municipality (7222299)
- National Natural Science Foundation of China (82372018 and 81701753)
This publication has 40 references indexed in Scilit:
- Molecular and Structural Insight into Adenosine A2A Receptor in Neurodegenerative Disorders: A Significant Target for Efficient Treatment ApproachMolecular Neurobiology, 2023
- Improved in vivo PET imaging of the adenosine A2A receptor in the brain using [18F]FLUDA, a deuterated radiotracer with high metabolic stabilityEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- How do adenosine A2A receptors regulate motor function?Parkinsonism & Related Disorders, 2020
- Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug developmentEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Synthesis and in vivo Evaluation of Fluorine‐18 and Iodine‐123 Pyrazolo[4,3‐e]‐1,2,4‐triazolo[1,5‐c]pyrimidine Derivatives as PET and SPECT Radiotracers for Mapping A2A ReceptorsChemMedChem, 2016
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews, 2012
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Adenosine A2A receptors and brain injury: Broad spectrum of neuroprotection, multifaceted actions and “fine tuning” modulationProgress in Neurobiology, 2007
- A novel approach for imaging brain–behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activatorNeuroImage, 2007
- Evaluation of [4‐O‐methyl‐11C]KW‐6002 as a potential PET ligand for mapping central adenosine A2A receptors in ratsSynapse, 2001